| Host: |
Rabbit |
| Applications: |
WB/IHC |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-Phospho-Interleukin-1 receptor-associated kinase 1-Thr387 (353-402 aa) is suitable for use in Western Blot and Immunohistochemistry research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:500-2000IHC-P 1:50-300 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
IRAK1 |
| Gene ID: |
3654 |
| Uniprot ID: |
IRAK1_HUMAN |
| Immunogen Region: |
353-402 aa |
| Specificity: |
Phospho-IRAK-1 (T387) Polyclonal Antibody detects endogenous levels of IRAK-1 protein only when phosphorylated at T387. |
| Immunogen: |
The antiserum was produced against synthesized peptide derived from the human IRAK1 around the phosphorylation site of Thr387 at the amino acid range 353-402 |
| Post Translational Modifications | Following recruitment on the activated receptor complex, phosphorylated on Thr-209, probably by IRAK4, resulting in a conformational change of the kinase domain, allowing further phosphorylations to take place. Thr-387 phosphorylation in the activation loop is required to achieve full enzymatic activity. Polyubiquitinated by TRAF6 after cell stimulation with IL-1-beta by PELI1, PELI2 and PELI3. Polyubiquitination occurs with polyubiquitin chains linked through 'Lys-63'. Ubiquitination promotes interaction with NEMO/IKBKG. Also sumoylated.leading to nuclear translocation. |
| Function | Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation. Association with MYD88 leads to IRAK1 phosphorylation by IRAK4 and subsequent autophosphorylation and kinase activation. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates the interferon regulatory factor 7 (IRF7) to induce its activation and translocation to the nucleus, resulting in transcriptional activation of type I IFN genes, which drive the cell in an antiviral state. When sumoylated, translocates to the nucleus and phosphorylates STAT3. |
| Protein Name | Interleukin-1 Receptor-Associated Kinase 1Irak-1 |
| Database Links | Reactome: R-HSA-1257604Reactome: R-HSA-166058Reactome: R-HSA-168638Reactome: R-HSA-209543 P51617-1Reactome: R-HSA-209560Reactome: R-HSA-445989Reactome: R-HSA-450302Reactome: R-HSA-450321Reactome: R-HSA-6811558Reactome: R-HSA-8986944Reactome: R-HSA-9020702Reactome: R-HSA-937039Reactome: R-HSA-9705671Reactome: R-HSA-975110Reactome: R-HSA-975138Reactome: R-HSA-975144Reactome: R-HSA-975155Reactome: R-HSA-975871 |
| Cellular Localisation | CytoplasmNucleusLipid DropletTranslocates To The Nucleus When SumoylatedRsad2/Viperin Recruits It To The Lipid Droplet |
| Alternative Antibody Names | Anti-Interleukin-1 Receptor-Associated Kinase 1 antibodyAnti-Irak-1 antibodyAnti-IRAK1 antibodyAnti-IRAK antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
